SEPN insider grant: CFO awarded 37,500 options at $11.70; vesting schedule disclosed
Rhea-AI Filing Summary
Septerna, Inc. Form 4 reports that Chief Financial Officer Gil M. Labrucherie acquired a stock option on 08/07/2025 to purchase 37,500 shares of common stock at an exercise price of $11.70 per share. The option is recorded as an acquisition and held directly by the reporting person.
The grant includes a service-based vesting schedule: 6/48th of the option shares vest on February 1, 2026, with the remaining shares vesting in 42 substantially equal monthly installments thereafter, subject to continuous service. The option shows an expiration/related date of 08/06/2035 and 37,500 shares are reported as beneficially owned following the transaction.
Positive
- Reporting person is identified as Chief Financial Officer Gil M. Labrucherie
- Grant is explicit: stock option to purchase 37,500 shares at $11.70 with a defined vesting schedule
Negative
- Options are not fully vested immediately: initial vesting on Feb 1, 2026 followed by 42 monthly installments
- The option represents future issuance of 37,500 shares upon exercise, which would increase outstanding shares if exercised
Insights
TL;DR: CFO received a routine option grant for 37,500 shares at $11.70; vesting ties value to continued service.
The Form 4 documents a standard executive equity award rather than an open-market purchase or disposition. Key metrics are a 37,500-share option with a stated exercise price of $11.70 and a multi-year vesting schedule (6/48th on Feb 1, 2026, then 42 monthly installments). Without the company’s current share count or market price in this filing, the immediate impact on per-share value cannot be quantified, but the grant is consistent with retention-focused compensation.
TL;DR: Grant follows a time-based vesting pattern and is reported under Section 16; disclosure appears complete for the transaction.
The disclosure identifies the reporting person as the Chief Financial Officer and records the transaction as an acquisition under Form 4, showing direct beneficial ownership of the option. The explicit vesting schedule and the option's expiration-related date (08/06/2035) are provided, which supports transparency on executive compensation timing. This filing documents a compensation event but does not itself indicate any governance violation.